Clinical trials: Blood Cancer
B-cell Adult Acute Lymphoblastic Leukemia, B-cell Chronic Lymphocytic Leukemia
Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/Lymphoma
This is a single-arm open-label phase I study to determine the effect of CD19- CAR-T Cells infusion followed by allogeneic stem cell transplantation in safety, efficacy and engraftment potential in patients with CD19+ B-lineage…
- Conditions
- B-cell Adult Acute Lymphoblastic Leukemia, B-cell Chronic Lymphocytic Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Hematopoietic/Lymphoid Cancer
- Trial name
- NCT03110640
- Testing
- anti-CD19 CAR-T, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 20 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
HEMATOLOGIC MALIGNANCIES
Conditioning Regimen Before Infusion of Allogeneic Hematopoietic Stem Cells
Unrelated Donor Hematopoietic Stem Cell Transplantation After Nonmyeloablative Conditioning for Younger Patients with Hematologic Malignancies.
- Trial name
- NCT00770523
- Where
- South Korea
- Volunteers
- 52 people
- Sponsor
- Cooperative Study Group A for Hematology
HIV Infections, Sexually Transmitted Infections
HIV Prevention Program for African American Teen Males
The purpose of this study is to test if sexual health interventions can reduce the incidence of STIs among African American teens (15 to 21 years old).
- Trial name
- NCT00849823
- Testing
- Male Sexual Health Program, Focus on the Future Program
- Where
- United States
- Volunteers
- 840 people, healthy volunteers welcome
- Sponsor
- Richard Crosby
Hepatitis B, Hepatocellular Carcinoma
Modified Process Hepatitis B Vaccine in Healthy Neonates (V232-056)
Hepatitis B Vaccine [Recombinant] is a well-established vaccine which has been used extensively, worldwide since its initial licensure in 1986.
- Trial name
- NCT00322361
- Testing
- Comparator: RECOMBIVAX HB™, Comparator: Modified process Hepatitis B Vaccine
- Volunteers
- 566 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Uterine Neoplasms, Cervical Cancer
Prospective Cohort Study of Minimal Residual Disease(MRD) Testing for Early Recurrence Detection in Endometrial and Cervical Cancer
This study aims to evaluate the clinical performance of blood-based Minimal Residual Disease (MRD) testing using circulating tumor DNA (ctDNA) in patients with endometrial and cervical cancer.
- Trial name
- NCT07382505
- Testing
- Serial blood collection for MRD testing
- Where
- South Korea
- Volunteers
- 600 people
- Sponsor
- Asan Medical Center
B-Cell Prolymphocytic Leukemia, Hypodiploidy
Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia
This phase II trial studies autologous peripheral blood stem cell transplant followed by donor bone marrow transplant in treating patients with high-risk Hodgkin lymphoma, non-Hodgkin lymphoma, multiple myeloma, or chronic…
- Conditions
- B-Cell Prolymphocytic Leukemia, Hypodiploidy, Loss of Chromosome 17p, Plasma Cell Leukemia
- Trial name
- NCT01008462
- Testing
- Allogeneic Bone Marrow Transplantation, Allogeneic Hematopoietic Stem Cell Transplantation, Autologous Hematopoietic Stem Cell Transplantation
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Fred Hutchinson Cancer Center
Moderate and Severe Haemophilia
HEAD-US SCORING SYSTEM: Assessment of the Real-world Impact of Ultrasound
Ultrasound represents a promising technique for the assessment of joint health in persons with haemophilia (PWH) by non-imaging specialists.
- Trial name
- NCT03237273
- Testing
- HEAD-US scoring system
- Volunteers
- 200 people
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Tacrolimus and Mycophenolate Mofetil in Preventing Acute Graft-Versus-Host Disease in Patients With Advanced Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation
RATIONALE: Tacrolimus and mycophenolate mofetil may be an effective treatment for graft-versus-host disease caused by donor stem cell transplantation.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00096096
- Testing
- mycophenolate mofetil, tacrolimus
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Bone Marrow Suppression, Brain and Central Nervous System Tumors
Combination Chemotherapy Plus Gene Therapy in Treating Patients With CNS Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Bone Marrow Suppression, Brain and Central Nervous System Tumors, Drug/Agent Toxicity by Tissue/Organ
- Trial name
- NCT00005796
- Testing
- filgrastim, gene therapy, lomustine
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Indiana University
Multiple Myeloma and Plasma Cell Neoplasm
Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow or peripheral stem cell transplantation may allow the doctor to give…
- Trial name
- NCT00003146
- Testing
- busulfan, melphalan, thiotepa
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Hematologic Malignancy, Haplo-identical HCT
CD45RA-depleted DLI for the Treatment of Refractory/Persistent Viral Infections After Haploidentical Transplantation
The goal of this clinical trial is to learn whether giving patients special donor immune cells (called "CD45RA Depleted DLI") can help treat viral infections that have not improved with standard antiviral drugs.
- Trial name
- CD45RADLITx (NCT07662369)
- Testing
- CD45RA depleted donor lymphocyte infusion (DLI)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Ruijin Hospital
Hematological Neoplasms, Recurrence
Peg Interferon α-2b for Relapsed Hematological Malignancies After Allo-HSCT
Aim: to observe the graft versus tumor effect of Pegylated Interferonα-2b in patients with hematological malignancies relapsed after allogeneic hematopoietic stem cell transplantation (alloHSCT) Patients: patients relapsed after…
- Trial name
- NCT02634294
- Testing
- Peg interferon alfa-2b
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Lymphoma, Neutropenia
Peripheral Stem Cell Transplantation to Prevent Neutropenia in Patients Receiving Chemotherapy for Relapsed or Refractory Non-Hodgkin's Lymphoma
RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy used to kill cancer cells.
- Trial name
- NCT00005787
- Testing
- epoetin alfa, filgrastim, recombinant flt3 ligand
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Northwestern University
Breast Neoplasms, Neoplasm Metastasis
Antimetabolite Induction, High-Dose Alkylating Agent Consolidation and Retroviral Transduction of the MDR1 Gene Into Peripheral Blood Progenitor Cells Followed by Intensification Therapy With Sequential Paclitaxel and Doxorubicin for Stage 4 Breast Cancer
This study examines the feasibility of using gene therapy to prevent some of the toxicities of an intensive chemotherapy regimen in patients with metastatic breast cancer.
- Trial name
- NCT00001493
- Testing
- peripheral blood progenitor cells carrying MDR1
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- National Cancer Institute (NCI)
Relapsed and Refractory, Lymphoid Hematological Malignancies
A Study of CD20/CD22 Targeted CAR T-cell Therapy for Relapsed or Refractory Lymphoid Malignancies
A Study of CD20/CD22 Targeted CAR T-cell Therapy for Relapsed or Refractory Lymphoid Malignancies.
- Trial name
- NCT04283006
- Testing
- CD20/CD22 dual Targeted CAR T-cells
- Where
- China
- Volunteers
- 100 people
- Sponsor
- He Huang
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia in Remission
Fludarabine Phosphate, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Peripheral Blood Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Malignancies
This phase II trial is studying the side effects and how well giving fludarabine phosphate, busulfan, anti-thymocyte globulin followed by donor peripheral blood stem cell transplant, tacrolimus, and methotrexate works in treating…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q)
- Trial name
- NCT01056614
- Testing
- fludarabine phosphate, busulfan, anti-thymocyte globulin
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Fred Hutchinson Cancer Center
Ewing's Sarcoma, Soft Tissue Sarcoma
Tandem Peripheral Blood Stem Cell (PBSC) Rescue for High Risk Solid Tumors
This study uses a double autologous peripheral blood stem cell rescue (PBSC) following dose-intensive chemotherapy for the treatment of high-risk pediatric solid tumors.
- Conditions
- Ewing's Sarcoma, Soft Tissue Sarcoma, Hepatoblastoma, Hodgkin's Disease
- Trial name
- NCT00179816
- Testing
- High-Dose Chemotherapy with Tandem PBSC Rescue.
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
Leukemia
Efficiency Study of Low Dose of IL-2 to Prevent Relapse in Standard Risk Leukemia After Transplantation
Hematopoietic stem cell transplantation (HSCT) is one of the best, and sometimes the only, option for the treatment of leukemia.
- Trial name
- NCT01517347
- Testing
- Interleukin-2
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Peking University People's Hospital
Multiple Myeloma and Plasma Cell Neoplasm
Rituximab in Treating Patients With Multiple Myeloma
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them. PURPOSE: Phase II trial to study the effectiveness of the monoclonal antibody rituximab in treating…
- Trial name
- NCT00003554
- Testing
- rituximab, melphalan, prednisone
- Where
- United States
- Sponsor
- The Cleveland Clinic
Multiple Myeloma
Bendamustine, Bortezomib (Velcade ®) and Prednisone (BVP) in Patients Newly Diagnosed Multiple Myeloma
This protocol corresponds to an open-label national phase II, multicenter, to assess efficacy (in terms of response rate and CR) and toxicity of bendamustine, bortezomib and prednisone (BVP) in 60 patients newly diagnosed MM.
- Trial name
- NCT01376401
- Testing
- Bendamustine, Velcade, Prednisone
- Where
- 14 sites in Spain
- Volunteers
- 60 people
- Sponsor
- PETHEMA Foundation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.